No one is taking into consideration the value of cytocom which imun owns 12 perc of. That's huge in itself.
That's true, but really no one knows anything about cytocom anymore. Their information is not current. Who knows what is happening there? Were the past trials successful or not? We just don't know, so it's hard to put an accurate value on that 12% of ownership I think.
News 
Market Data 
Discover 
